GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

D.Western Therapeutics Institute 4576.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

50

0.00%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥387.6m

FY2016FY2025

Net income

−¥632.1m

FY2016FY2025

Free cash flow

−¥496.5m

FY2016FY2025

Shareholders' equity

¥1.44bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue¥387.6m¥471.6m¥428.4m¥448.1m¥414.4m¥355.6m¥580.5m¥292.9m¥254.0m¥168.0m
Research and development¥669.8m¥1.37bn¥930.5m¥469.6m¥316.2m¥350.5m¥249.4m¥795.3m¥603.3m¥227.0m
Operating income−¥619.9m−¥1.27bn−¥824.3m−¥425.4m−¥171.6m−¥284.8m¥117.3m−¥796.0m−¥633.7m−¥319.7m
Net income−¥632.1m−¥1.29bn−¥812.4m−¥429.7m−¥149.0m−¥276.1m¥133.2m−¥749.0m−¥1.56bn−¥253.5m
Diluted earnings per share-11.08-32.63-25.28-14.17-5.08-9.445.07-28.55-59.48-4.41

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets¥2.17bn¥1.67bn¥2.37bn¥2.96bn¥2.46bn¥2.74bn¥1.98bn¥2.07bn¥2.88bn¥2.91bn
Cash and short-term investments¥1.71bn¥1.13bn¥1.87bn¥2.33bn¥1.93bn¥2.31bn¥1.54bn¥1.58bn¥2.13bn¥2.65bn
Total liabilities¥734.0m¥935.6m¥1.09bn¥1.08bn¥427.7m¥573.8m¥573.3m¥773.7m¥781.6m¥35.5m
Debt¥605.2m¥798.0m¥885.1m¥967.7m¥340.0m¥460.0m¥480.0m¥600.0m¥600.0m—
Shareholders' equity¥1.44bn¥733.9m¥1.28bn¥1.86bn¥2.01bn¥2.16bn¥1.39bn¥1.26bn¥2.00bn¥2.74bn
Shares outstanding57m40m32m30m29m29m26m26m26m57m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−¥493.8m−¥1.30bn−¥586.8m−¥354.8m−¥176.3m−¥216.3m¥175.0m−¥540.0m−¥797.0m−¥333.0m
Capital spending−¥2.7m−¥9.0m−¥14.9m−¥9.8m−¥2.9m−¥5.1m−¥5.0m−¥6.0m−¥4.0m−¥37.8m
Free cash flow−¥496.5m−¥1.31bn−¥601.8m−¥364.6m−¥179.2m−¥221.4m¥170.0m−¥546.0m−¥801.0m−¥370.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥18.0m¥15.1m¥90.5m¥123.9m¥76.2m¥96.8m¥122.7m¥125.4m
Operating income−¥145.7m−¥167.3m−¥141.4m−¥169.4m−¥167.0m−¥142.0m−¥562.0m−¥197.8m
Net income−¥152.3m−¥170.8m−¥139.4m−¥175.8m−¥165.8m−¥150.2m−¥563.1m−¥206.5m
Diluted earnings per share-2.65-2.97-2.44-3.08-2.91-2.63-14.24-5.22
Total assets¥2.05bn¥1.97bn¥2.17bn¥2.18bn¥1.51bn¥1.60bn¥1.67bn¥2.19bn
Cash and short-term investments¥1.58bn¥1.54bn¥1.71bn¥1.65bn¥1.05bn¥1.14bn¥1.13bn¥1.16bn
Debt¥583.2m¥126.5m¥605.2m¥46.5m¥518.0m¥19.0m¥19.0m¥19.0m
Shareholders' equity¥1.41bn¥1.31bn¥1.44bn¥1.46bn¥884.6m¥1.00bn¥733.9m¥1.02bn

Financial ratios

Data as of 14 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-159.9%-272.2%-192.4%-97.5%-37.5%-80.1%
Net margin-163.1%-273.6%-189.7%-95.9%-36.0%-77.6%
Return on equity-44.0%-175.8%-63.5%-23.1%-7.4%-12.8%
Return on assets-29.1%-77.3%-34.2%-14.5%-6.0%-10.1%
Free cash flow yield-12.3%-46.6%-25.4%-16.2%-8.4%-10.3%
Revenue growth-17.8%10.1%-4.4%8.1%16.5%-38.7%
Earnings growth-51.0%58.8%89.1%188.4%-46.0%-307.3%
Current ratio9.91x11.12x11.02x12.59x11.19x11.93x
Debt to equity0.42x1.09x0.69x0.52x0.17x0.21x
Equity ratio66.2%44.0%53.9%62.8%81.5%79.0%
Interest coverage-70.32x-246.35x-331.05x-138.90x-35.10x-60.24x
R&D as a share of sales172.8%290.0%217.2%104.8%76.3%98.6%
Buybacks as a share of market value-44.3%-23.0%-5.9%-3.3%-0.4%-11.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.7%1.7%20.3%
Operating income13.4%16.8%7.9%
Net income13.7%18.0%7.9%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-220.2%-181.0%-143.6%-143.0%
Net margin-223.7%-182.3%-143.3%-163.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-8.7-6.2-5.6-18.5-42.6-30.6128.0-20.1-8.6-92.5
Price to sales14.116.910.617.715.323.829.451.453.0139.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.